Shareholders' Equity Equity Issuances (Details)			1 Months Ended	9 Months Ended	12 Months Ended
	Sep. 14, 2016 USD ($) clinical_trial_subject $ / shares shares	Mar. 10, 2016 USD ($) $ / shares shares	Nov. 30, 2015 USD ($) shares	Sep. 30, 2016 shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 shares	Sep. 30, 2015 shares	May 01, 2015 USD ($)
Class of Stock [Line Items]
Common stock, shares, issued (shares) | shares		141,844
Common Stock Warrants, Shares | shares		141,844				321,404
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 10.00
Share Price | $ / shares		$ 7.05
Proceeds from Issuance of Warrants		$ 1,000,000
May 2015 Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common stock, shares, issued (shares) | shares							36,484
Purchase Commitment, Remaining Minimum Amount Committed								$ 30,000,000
RD Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues | shares	847,458
Shares Issued, Price Per Share | $ / shares	$ 4.72
Proceeds from Issuance of Common Stock	$ 4,000,000
Private Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues | shares				1,398,305
Proceeds from Issuance of Common Stock					$ 6,600,000
Purchase Commitment, Maximum Amount Committed, Shares | shares	4,449,153
Proceeds from Issuance of Common Stock, Initial Closing	$ 12,600,000
Proceeds from Issuance of Common Stock, Second Closing	$ 8,400,000
Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing | clinical_trial_subject	70
Proceeds from Issuance of Common Stock, Initial Closing, Receivable					6,000,000
Proceeds from Issuance of Common Stock, Second Closing, Receivable					$ 4,000,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase Commitment, Maximum Amount Committed, Shares | shares			1,101,928
Purchase Commitment, Remaining Minimum Amount Committed			$ 30,000,000
Term Of Agreement In Months			24 months
Shares, Issued | shares					109,270
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares					$ 300,000
Discount Applied To Weighted Average Price			5.00%